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Background: A consensus on a central line-associated bloodstream infection (CLABSI) surveillance deﬁnition
in home infusion is needed to standardize measurement and benchmark CLABSI to provide data to drive
improvement initiatives
Methods: Experts across ﬁelds including home infusion therapy, infectious diseases, and healthcare epidemiology convened to perform a 3-step modiﬁed Delphi approach to obtain input and achieve consensus on a
candidate home infusion CLABSI deﬁnition.
Results: The numerator criterion was identiﬁed by participants as involving one of the 2 following: (1) recognized
pathogen isolated from blood culture and pathogen is not related to infection at another site, or (2) one of the
following signs or symptoms: fever of 38°C (100.4°F), chills, or hypotension (systolic blood pressure ≤90 mm Hg),
and one of the 2 following: (A) common skin contaminant isolated from 2 blood cultures drawn on separate
occasions and organism is not related to infection at another site, or (B) common skin contaminant isolated from
blood culture from patient with intravascular access device and provider institutes appropriate antimicrobial
therapy. The criteria for a denominator included days from the day of admission with a central venous catheter to
day of removal of central venous catheter. In addition, 11 inclusion criteria and 4 exclusion criteria were included.
Discussion: Home infusion therapy and healthcare epidemiology experts developed candidate criteria for a
home infusion CLABSI surveillance deﬁnition.
Conclusions: Home care and home infusion agencies can use this deﬁnition to monitor their own CLABSI
rates and implement preventative strategies.
© 2019 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All
rights reserved.
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Annually, 1.2 million use long-term central venous catheters
(CVCs) at home for chemotherapy, total parenteral nutrition, outpatient parenteral antimicrobial therapy, and other indications.1 Unlike
in hospitals, patients receiving these therapies through home care,
home infusion, or home hospice agencies, and their caregivers (eg,
family, friends, neighbors, and coworkers) perform day-to-day CVC
care and initiate infusion therapy after being trained and deemed
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competent by home care nurses. Patients maintaining CVCs at home
are at risk for developing central line-associated bloodstream infections (CLABSIs). CLABSIs developing outside of acute care hospitals
can outnumber acute care CLABSIs.2
National policies have led to widely-accepted acute care CLABSI
surveillance deﬁnitions3-7 reportable through the Centers for Disease
Control and Prevention’s National Healthcare Safety Network
(NHSN).4,8,9 With uniform CLABSI surveillance deﬁnitions, benchmarked rates, and mandated reporting, quality improvement initiatives using evidence-based intervention bundles have contributed to
a 50% drop in acute care CLABSI rates.10-13
In order to benchmark home infusion CLABSI data in home infusion patients and to similarly allow for large-scale quality improvement initiatives, there is an urgent need for an improved home
infusion CLABSI deﬁnition. The Association of Professionals in Infection Control (APIC) developed a deﬁnition of home healthcare-associated bloodstream infections14 relying on NHSN acute care CLABSI
criteria available in 2008, but this deﬁnition has not been widely
adopted.4,15 We recently showed that signiﬁcant variation exists
nationwide in home infusion CLABSI reporting.16 In particular, it is
unclear how to deﬁne, collect, and record denominator data.17 Determining attribution is also difﬁcult, especially if the CVC is accessed
both in the home and in an outpatient clinic, or if a home infusion
agency provides product to a patient but a noncontracted home nursing agency provides education.17 Other challenges with surveillance
include accessing inpatient records to access laboratory test results
when a blood culture is drawn in an acute care setting, and lack of
trained infection preventionists in most home infusion agencies.16,17
To address the need for a CLABSI deﬁnition in the home, we gathered stakeholders in healthcare epidemiology, infection prevention,
measure development, infusion nursing, and home infusion therapy
to acquire input and achieve consensus around a home infusion
CLABSI surveillance deﬁnition.
METHODS
We performed a modiﬁed 3-stage Delphi approach to identify
components of a deﬁnition of CLABSI for home infusion therapy, consisting of a ranking evaluation, consensus meeting, and ﬁnal ranking
evaluation18-20 (Fig 1).
Systematic literature review
A systematic literature review was conducted to inform the components of a deﬁnition of CLABSI in home infusion therapy, focusing
on the elements used in the NHSN acute care CLABSI deﬁnition.7
These were numerator criteria (or what would be considered a
CLABSI), denominator criteria (how to measure CVC days), inclusion
criteria (the population eligible to develop a CLABSI), and exclusion
criteria (the population excluded from eligibility criteria from CLABSI
surveillance).16,21 We focused on criteria used by researchers studying CLABSI or other bloodstream infections in home infusion therapy,
as well as reports of what may be used nationally in monitoring or
reporting for patients.
The search strategy was developed with the assistance of a medical librarian using variations of key MeSH terms associated with

home infusion therapy and CLABSI or bloodstream infection
(Appendix 1). The search strategy was applied for the period of January 1, 1980 through January 7, 2019. This search strategy was applied
to PubMed, Cochrane Library, and Embase databases. Hand searches
were conducted of the reference lists of retrieved articles, and additional literature identiﬁed through knowledge of the researchers. We
also included bloodstream infection surveillance deﬁnitions used in
other healthcare settings, particularly the acute care NHSN CLABSI
criteria and the NHSN dialysis event surveillance.
Studies were considered for review if they described numerator,
denominator, inclusion, or exclusion criteria for CLABSI or bloodstream
infection in home infusion therapy, descriptions of CLABSI surveillance
activities in home infusion therapy, or guidelines for CLABSI deﬁnitions
in other healthcare settings. These descriptions of components of CLABSI
deﬁnitions could have been in descriptions of an intervention, guideline,
description of expert opinion, survey of common practices, or description of a cohort. Studies including adult or pediatric patients were eligible. Numerator, denominator, inclusion, and exclusion criteria were
abstracted for each paper (Appendix 2).

Formation of the expert panel
We sought expertize from a United States-based multidisciplinary
panel of experts in home infusion therapy, healthcare epidemiology,
infectious diseases, infection prevention, home parenteral nutrition
(HPN), and home infusion nursing. We reached out to authors of
studies identiﬁed in the systematic review and experts who have
been involved in home health quality collaborations. In addition, we
reached out to those who had responded to a prior survey of members of the Infusion Nurses Society, Society for Healthcare Epidemiology of America Research Network, and the National Home Infusion
Association16 as well as leadership of the Society for Healthcare Epidemiology of America Research Network, the Infusion Nurses Society,
the Pediatrics at Home Collaborative, the National Home Infusion
Association, and the American Society for Parenteral and Enteral
Nutrition. Experts were asked if they had experience with CLABSI
surveillance in home infusion therapy.

First stage of Delphi: Ranking evaluation
The expert panel completed an electronic survey listing numerator, denominator, inclusion, and exclusion criteria identiﬁed in the
literature review, with separate categories for pediatric criteria
(Appendix 3). Experts were asked to rate each criteria for importance
of the criteria and for feasibility of implementation of the criteria in
home infusion therapy on a range of 1-9, where 9 was very important
or very feasible. Respondents could also propose additional criteria.
The survey was piloted with 3 members of the expert panel and clariﬁcations were made to the instructions based on their comments.
This ﬁrst survey was distributed March through April 2019. Respondents were given 4 weekly reminder emails to complete the survey.
Descriptive statistics were used to summarize survey results. Mean
scores of 7-9 on importance were considered high scores, 5-6 were considered moderate scores, and <5 were considered low scores and were
excluded in later rounds of the Delphi approach.

Fig 1. Performance of a 3-stage modiﬁed Delphi approach.
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inclusion and exclusion criteria, all with an importance score ≥7 and
a feasibility score ≥6 were included.

Second stage of Delphi: Consensus meeting
Members of the expert panel were then invited to a 2-hour meeting on June 6, 2019 over a remote web-based platform to discuss the
results of the ﬁrst survey. Participants in the expert panel meeting
reviewed summary data prior to the meeting. Participants in the
expert panel meeting discussed each criterion with a mean importance rating ≥5, as well as additional suggestions proposed by the
expert panel. Criteria that were determined unimportant or infeasible by the expert panel meeting participants were considered for
removal from the ﬁnal survey. Participants in the expert panel meeting also proposed additional criteria and modiﬁcations of existing criteria. The discussion was recorded and transcribed to ensure no
comments were missed.
Third stage of Delphi: Ranking evaluation
A second survey was distributed to the entire expert panel,
including those who did not participate in the meeting. Criteria
included on this survey were those ranked with an importance score
of ≥5 on the ﬁrst survey that were viewed positively by the expert
panel, criteria proposed by respondents to the ﬁrst survey that were
viewed positively by the expert panel, modiﬁcations of existing criteria as proposed by the expert panel, and new criteria proposed in by
the expert panel.
Using the same overall categories of numerator, denominator,
inclusion, and exclusion criteria, with subcategories for pediatric
patients, we asked participants to rate each proposed criteria on 2
scales focusing on importance and on feasibility. Each scale ranged
from 1 to 9, where 9 was highly important or highly feasible.
The electronic survey was distributed to the expert panel members throughout July 2019. Expert panel members were given 4
weekly reminder emails to complete the survey.
Final deﬁnition components
Final survey results including descriptive statistics were returned
to the expert panel for ﬁnal comments and feedback, and no major
objections were raised. For the numerator and denominator, the criteria ranked highest on the importance scale were included in the
ﬁnal deﬁnition, assuming the feasibility score was ≥6. For the

Ethics
The study was approved by the Johns Hopkins University School
of Medicine Institutional Review Board.
RESULTS
Of an initial 234 potential articles, we excluded 12 duplicate
articles and 5 non-English language articles to review 217 abstracts
in full (Appendix Fig 1). We excluded 13 articles which did not focus
on home infusion and 47 conference abstracts with incomplete methods, then reviewed 157 articles in their entirety. After applying criteria as outlined in the Methods, 49 articles were included in the
evidence summary, with an additional 7 articles identiﬁed through
knowledge of the literature. Data was abstracted and made available
to the expert panel (Appendix Table 2).
A total of 46 respondents agreed to participate in the process. Of
these, 21 completed the ﬁrst survey (46%, Table 1). These were primarily home health or home infusion nurses (N = 11, 52%) and infectious diseases physicians (N = 6, 29%). Most worked primarily with
adults (N = 14, 67%). Respondents rated the following: 28 numerator
criteria with an additional 4 pediatric numerator criteria, 11 denominator criteria, 11 inclusion criteria, and 9 exclusion criteria with an
additional pediatric exclusion criteria (Appendix Table 2). In addition,
respondents submitted 2 additional denominator criteria and 4 additional inclusion criteria for consideration.
Based on these rankings, we removed from consideration criteria
with a rating of importance or of feasibility <5 (Appendix Table 2).
Twenty-two candidate numerator criteria, 3 pediatric-speciﬁc
numerator criteria, 6 denominator criteria, 8 inclusion criteria, and 7
exclusion criteria, remained, as well as a pediatric-speciﬁc exclusion
criterion. Each of the pediatric-speciﬁc criteria was targeted to neonates and infants ≤1 year of age, so we also deﬁned pediatric criteria
as those ≤1 year of age.
During the remotely-facilitated live conversation, of the original
46 participants, 18 participated, including 5 infectious diseases physicians, 4 hospital epidemiologists, and 9 home infusion or home
health nurses. After this conversation, 9 numerator criteria were

Table 1
Composition of expert panel and participation in elements of the modiﬁed Delphi approach to developing a consensus around home infusion central line-associated bloodstream
infection

Roles, population and area of expertize
Role:
Home care or infusion nursing and quality improvement
Infection preventionist
Infectious diseases physician
Nutritionist
Healthcare epidemiologist
Home health/infusion Medical/nursing director
Self-identiﬁed population of expertize:
Primarily sees adults
Primarily sees children
Sees both adults and children
Unspeciﬁed/Not asked
Self-identiﬁed area of expertize:
Home infusion therapy
Healthcare-associated infection surveillance
Both
Unspeciﬁed/Not asked
Total (N, % of total)

Volunteered
to participate N, %

Participated in
Delphi survey
#1 N, %

Participated
in web-based
expert panel
discussion N, %

Participated in
Delphi survey
#2 N, %

27, 59%
9, 19.5%
9, 19.5%
1, 2%
5, 11%
7, 15%

11, 52%
3, 14%
6, 29%
1, 5%
3, 14%
4, 19%

9, 53%
3, 18%
5, 29%
4, 24%
2, 12%

11, 52%
5, 24%
5, 24%
4, 19%
3, 14%

14, 30%
5, 11%
8, 17%
19, 41%

14, 67%
3, 14%
4, 19%
-

7, 41%
4, 24%
3, 18%
3, 18%

10, 48%
5, 24%
6, 29%
-

8, 17%
7, 15%
11, 24%
20, 43%
46, 100%

7, 33%
7, 33%
6, 29%
1, 5%
21, 46%

5, 29%
2, 12%
7, 41%
3, 18%
17, 37%

8, 38%
5, 24%
8, 38%
21, 46%
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Table 2
Candidate criteria for components of numerator deﬁnitions, or something that would be used in a deﬁnition of a CLABSI in home infusion therapy, after initial rating and web-based
discussion. Criteria were rated on their importance and feasibility on a scale of 1-9, where 9 was very important or very feasible

Numerator criteria
NNIS criteria: ONE of the two following: (1) recognized pathogen isolated from blood culture AND pathogen is not
related to infection at another site, OR (2) one of the following signs or symptoms: fever of 38°C (100.4°F), chills, or
hypotension (systolic blood pressure ≤90 mm Hg), AND one of the two following: (A) common skin contaminant
isolated from two blood cultures drawn on separate occasions AND organism is not related to infection at another site,
OR (B) common skin contaminant isolated from blood culture from patient with intravascular access device AND
provider institutes appropriate antimicrobial therapy.27,2,3,31,36,38,42,52
APIC/HICPAC criteria: ONE of the three following: (1) patient has a recognized pathogen from one or more blood
cultures AND organism cultured from blood is not related to an infection at another site, OR (2) patient has fever, chills
or hypotension AND signs or symptoms not related to an infection at another site AND common skin contaminant in
≥2 cultures drawn on two separate occasions.18
NHSN Criteria: LCBI 1: Patient has a recognized bacterial or fungal pathogen not on the common commensal list,
identiﬁed from one or more blood specimens obtained by a culture or nonculture based microbiologic testing
methods AND organism is not related to an infection at another site. OR LCBI 2: Patient has at least one of the three
following signs or symptoms: fever (>38°C), chills, or hypotension, AND organism identiﬁed in blood is not related
to an infection at another site AND the same common commensal is identiﬁed by a culture or non-culture based
microbiological testing method from two or more blood specimens collected on separate occasions.6,36,38,42,46,51,52
Pediatric numerator criteria
Patient up to one year of age has at least one of the following: fever (≥38°C), hypothermia (<36°C), apnea, or
bradycardia, AND organism identiﬁed in blood is not related to an infection at another site AND the same common
commensal is identiﬁed by a culture or non-culture based microbiological testing method from two or more blood
specimens collected on separate occasions.6
Patient ≤1 year of age has at least one of the following signs or symptoms: fever (>38°C, rectal), hypothermia
(<37°C, rectal), apnea, or bradycardia and positive laboratory results are not related to an infection at another site,
AND at least one of the following: (1) common skin contaminant is cultured from two or more blood cultures drawn
on separate occasions, OR (2) common skin contaminant is cultured from at least one blood culture from a patient
with a CVC, and provider institutes appropriate antimicrobial therapy, OR (3) positive antigen test on blood or urine.(2)
Variant: Patient ≤1 year of age with a CVC has at least one of the following signs or symptoms: fever (>38°C, rectal),
hypothermia (<36°C, rectal), apnea, or bradycardia and positive laboratory results are not related to an infection at
another site, AND at least one of the following: (1) common skin contaminant is cultured from two or more blood
cultures drawn on separate occasions, OR (2) organism not considered a common skin contaminant is cultured in one
culture, OR (3) positive antigen test on blood or urine.(2)

Importance rating mean
(standard deviation, N)

Feasibility rating mean
(standard deviation, N)

7.81 (1.76, 21)

6.81 (2.40, 21)

7.35 (2.15, 20)

5.95 (2.73, 20)

7.33 (1.98, 21)

6.95 (2.46, 21)

Importance rating mean
(standard deviation, N)

Feasibility rating mean
(standard deviation, N)

7.68 (1.81, 19)

6.89 (2.49, 18)

7.11 (2.25, 19)

5.82 (2.75, 18)

7.00 (2.18, 19)

6.28 (2.76, 17)

ANC, absolute neutrophil count; APIC, Association for Professionals in Infection Control and Epidemiology; BSI, bloodstream infection; CLABSI, central line-associated bloodstream
infection; CVC, central venous catheter; HPN, home parenteral nutrition; HICPAC, Healthcare Infection Control Practices Advisory Committee; LCBI, laboratory-conﬁrmed bloodstream infection; NHSN, National Healthcare Safety Network; NNIS, National Nosocomial Infections Surveillance; PICC, peripherally inserted central catheter; WBC, white blood cell.

maintained, and 4 additional criteria proposed.22 In addition, 2 pediatric-speciﬁc numerator criteria were maintained, with one additional pediatric-speciﬁc numerator criterion suggested. Four
denominator criteria were maintained, with an additional 4 denominator criteria suggested; 16 inclusion criteria were maintained, with
an additional 4 inclusion criteria suggested; and 7 exclusion criteria
were maintained, with an additional 6 suggested (Appendix Table 3).
During the conversation stage of the Delphi, participants agreed
that a focus should be placed on meaningful and feasible measures
over highly sensitive or speciﬁc measures. While there was debate
around the predictive value of a clinician ordering an antimicrobial
agent in response to a single positive culture and around the challenges accessing these data, it was thought that the NNIS deﬁnition
got at the intent of the patient having a CLABSI. Participants described
challenges applying these criteria such as not having the ability to
monitor patient signs and symptoms easily, not acquiring blood culture results in a timely fashion, differences in blood culturing techniques, difﬁculties accounting for new technologies for diagnosing
bacteremia that do not rely on cultures, trouble accessing inpatient
chart data, and trouble identifying the time between when different
cultures were drawn when a home health nurse may drive several
miles to drop off the tests. In addition, very lengthy criteria were
thought to be difﬁcult to implement in home infusion therapy.
Twenty-eight participants completed the ﬁnal survey, including
11 home health or home infusion nurses (39%), 7 healthcare epidemiologists (25%), 5 infectious diseases physicians (18%), and 5
infection prevention nurses (18%). Highly-rated numerator criteria

ratings are described in Table 2 (all numerator criteria ratings are
described in Appendix Table 4), while highly-ranked denominator
criteria ratings are described in Table 3 (all denominator criteria
ratings as well as inclusion, and exclusion criteria are described in
Appendix Table 5).
After the ﬁnal survey, the most highly-rated numerator criteria on
importance (those with mean scores of ≥7) included the National
Nosocomial Infections Surveillance system acute care surveillance
deﬁnition23 (NNIS, score 7.81), the Association for Professionals in
Infection Control-Healthcare Infection Control Practices Advisory
Committee home care bloodstream infection surveillance deﬁnition14
(APIC-HICPAC, score 7.35), and a modiﬁcation of the NHSN acute care
CLABSI surveillance deﬁnition7 (score 7.35) (Table 2). Of these, the
modiﬁcation of the NNIS and NHSN surveillance deﬁnitions were
rated ≥7 on feasibility (mean scores 6.81 and 6.95, respectively). For
pediatric patient numerator criteria, acute care CLABSI NHSN criteria
had the highest importance score7 (mean 7.68).
For denominator criteria, the most highly-rated criteria on importance (mean scores ≥7) included device days (score 7.95); days from
day of admission to home infusion services with a CVC to day of
removal of CVC, subtracting time spent in acute care hospitals (score
7.50); and device days standardized to per 1,000 home catheter days
(score 7.48) (Table 3).
The ﬁnal numerator criteria included one of the 2 following: (1)
recognized pathogen7 isolated from blood culture AND pathogen7 is
not related to infection at another site, OR (2) one of the following
signs or symptoms: fever of 38°C (100.4°F), chills, or hypotension
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Table 3
Highly-ranked candidate denominator criteria for a possible deﬁnition of a CLABSI in home infusion therapy, after initial rating and web-based discussion. Criteria were rated on
their importance and feasibility on a scale of 1-9, where 9 was very important or very feasible

Denominator criteria
Device (CVC) days.27
Additional suggestion (device days deﬁnition): Day of admission to home infusion services with a CVC to the day
of CVC removal, subtracting time spent in acute care hospitals.
Per 1,000 home CVC days.30,31,33-35,37,38,43,44,48,53,59,61,65,70-72,74
CVC placement date OR date of admission to home care agency TO date of discharge from home care.33

Importance rating mean
(standard deviation, N)

Feasibility rating mean
(standard deviation, N)

7.95 (2.10, 21)
7.50 (1.47, 20)

7.29 (1.88, 21)
6.50 (1.86, 20)

7.48 (2.01, 21)
6.95 (2.17, 21)

6.29 (2.27, 21)
7.52 (1.71, 21)

ANC, absolute neutrophil count; APIC, Association for Professionals in Infection Control and Epidemiology; BSI, bloodstream infection; CLABSI, central line-associated bloodstream
infection; CVC, central venous catheter; HICPAC, Healthcare Infection Control Practices Advisory Committee; HPN, home parenteral nutrition; NHSN, National Healthcare Safety Network; NNIS, National Nosocomial Infections Surveillance; PICC, peripherally inserted central catheter; WBC, white blood cell.

(systolic blood pressure ≤90 mm Hg), AND one of the 2 following: (A)
common skin contaminant7 isolated from 2 blood cultures drawn on
separate occasions (different venipunctures, a combination of venipuncture and lumen withdrawal, or different lumens of the same
central line; or at different times)7 AND organism is not related to
infection at another site, OR (B) common skin contaminant7 isolated
from blood culture from patient with intravascular access device
AND provider institutes appropriate antimicrobial therapy (antimicrobial active against the organism initiated between 2 days prior
and 2 days after the blood culture, Table 4). For pediatric numerator
criteria, the ﬁnal criteria included patient up to 1 year of age has at
least one of the following: fever (≥38°C), hypothermia (<36°C),
apnea, or bradycardia (heart rate <100 beats per minute), AND

organism identiﬁed in blood is not related to an infection at another
site AND the same common commensal7 is identiﬁed by a culture or
nonculture based microbiological testing method from 2 or more
blood specimens collected on separate occasions (different venipunctures, a combination of venipuncture and lumen withdrawal, or different lumens of the same central line; or at different times).7 The
initial denominator criteria included “device days.” In ongoing conversations, the deﬁnition of “device days” required further clariﬁcation, particularly if a home infusion CLABSI deﬁnition were to be used
for attribution. Therefore, “device days” were deﬁned as the day of
admission to home infusion services with a CVC to the day of removal
of the CVC or discharge from home infusion services, subtracting time
spent in acute care hospitals.

Table 4
Agreement on candidate criteria for CLABSI in home infusion therapy, including mean ratings on importance to include and feasibility to implement, on a scale of 1-9, where 9 was
very important or very feasible

Numerator criteria
ONE of the two following: (1) recognized pathogen7 isolated from blood culture AND pathogen is not related to infection
at another site, OR (2) one of the following signs or symptoms: fever of 38°C (100.4°F), chills, or hypotension (systolic
blood pressure ≤90 mm Hg), AND one of the two following: (A) common skin contaminant7 isolated from two blood
cultures drawn on separate occasions (different venipunctures, a combination of venipuncture and lumen withdrawal, or different lumens of the same central line; or at different times)7 AND organism is not related to infection at
another site, OR (B) common skin contaminant7 isolated from blood culture from patient with intravascular access
device AND provider institutes appropriate antimicrobial therapy (antimicrobial active against the organism initiated
between two days prior and two days after the blood culture).27,2,3,31,36,38,42,52
Pediatric numerator criteria (in those ≤1 year of age)
Patient up to one year of age has at least one of the following: fever (≥38°C), hypothermia (<36°C), apnea, or bradycardia
(heart rate <100 beats per minute), AND organism identiﬁed in blood is not related to an infection at another site AND
the same common commensal7 is identiﬁed by a culture or nonculture based microbiological testing method from
two or more blood specimens collected on separate occasions (different venipunctures, a combination of venipuncture and lumen withdrawal, or different lumens of the same central line,7 or at different times).6
Denominator criteria
Device days deﬁned as: day of admission to home infusion services with a CVC to the day of CVC removal, subtracting
time spent in acute care hospitals, per 1,000 home-catheter days.
Patients who would be excluded from the home infusion CLABSI criteria.
Had a CVC within the 48-hour period before the development of the BSI.51
In home care at least 48 hours.29,33,35,39
Has a CVC that terminates at or close to the heart, or in one of the great vessels that is used for infusion or withdrawal of
blood.6
Anyone in whom home infusion staff accessed an implanted port or CVC.35
Include CVC even if it has migrated from the great vessels.6
Implanted ports accessed within the last 72 hours.
A CVC has been in place for at least two consecutive calendar days.6
Anyone in whom home infusion or home health staff taught the patient or caregivers how to manage the CVC.35
Anyone in whom home infusion or home health staff performed a CVC dressing or cap change.35
Anyone in whom staff inserted a PICC.35
Anyone in whom staff de-accessed an implanted port.35
Patients who would be excluded from the home infusion CLABSI criteria.
Hospital readmission within two days of hospital discharge.58
Midlines or peripheral venous catheters.6
Patients with Ventricular Assist Device.6
Munchausen Syndrome (or by proxy, known or suspected).6
BSI, bloodstream infection; CVC, central venous catheter; PICC, peripherally inserted central catheter.

Importance mean
(standard deviation, N)

Feasibility mean
(standard deviation, N)

7.81 (1.76, 21)

6.81 (2.40, 21)

7.68 (1.81, 19)

6.89 (2.49, 18)

7.50 (1.47, 20)

6.50 (1.86, 20)

8.33 (1.73, 21)
8.33 (1.39, 21)
8.19 (1.56, 21)

7.90 (1.90, 21)
8.30 (1.38, 20)
7.95 (1.73, 21)

7.62 (1.70, 21)
7.42 (2.28, 19)
7.38 (1.91, 21)
7.33 (1.94, 21)
7.14 (2.12, 21)
6.86 (2.17, 21)
6.62 (2.90, 21)
6.43 (2.15, 21)

7.76 (1.92, 21)
6.89 (2.49, 19)
7.19 (1.82, 21)
6.90 (2.02, 21)
7.33 (2.08, 21)
7.00 (2.18, 21)
7.33 (2.57, 21)
7.38 (1.91, 21)

8.29 (1.61, 21)
8.29 (1.16, 21)
7.38 (2.57, 21)
7.10 (2.58, 21)

8.10 (1.74, 21)
7.85 (1.19, 20)
6.67 (2.66, 21)
5.24 (2.76, 21)
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The most highly-rated inclusion criteria based on importance
included having a CVC ≥48 hours before the development of the
bloodstream infection (score 8.33), being in home care ≥48 hours
(score 8.33), and having a CVC terminating at or close to the heart per
documentation from the acute care hospital or provider placing the
CVC (score 8.19) (Table 3). Other highly-rated criteria included anyone in whom home infusion staff accessed an implanted port or CVC
(score 7.62), a CVC even if it migrated (score 7.42), an implanted port
accessed ≥72 hours (score 7.38), a CVC that had been in place ≥2 consecutive calendar days (score 7.33) and anyone in whom contracted
or employed staff taught the patient or caregivers how to self-manage the CVC (score 7.14). Additional inclusion criteria rated highly on
mean feasibility included anyone in whom the staff performed CVC
dressing or cap changes (score 7.00), anyone in whom the staff
inserted a peripherally-inserted central catheter (score 7.33), and
anyone in whom staff deaccessed an implanted port (score 7.38). All
of these were included in the ﬁnal deﬁnition (Table 4).
The most highly-rated exclusion criteria based on importance
included those readmitted to the hospital ≤2 days of hospital discharge (score 8.29), patients with only midlines or peripheral intravenous catheters (score 8.29), patients with ventricular assist devices
(score 7.38), and patients with Munchausen Syndrome by proxy,
either known or suspected (score 7.10) (Table 3). All of these were
included in the ﬁnal deﬁnition (Table 4).
DISCUSSION
This study gathered experts to rate candidate criteria for home
infusion CLABSI surveillance deﬁnitions. Our criteria (Table 4) can be
used as a starting point for providers of home infusion therapy to perform CLABSI surveillance and quality improvement interventions to
reduce CLABSI rates.
We noted substantial variation in deﬁnitions used by prior
studies and stakeholders for CLABSI deﬁnitions in home infusion
therapy.14-16,23-77 Respondents to a survey of home infusion professionals, healthcare epidemiologists, and infusion nurses noted many barriers to home infusion CLABSI reporting, such as difﬁculty accessing
culture data, insufﬁcient or inadequately trained staff to perform
CLABSI surveillance, not appreciating the importance of CLABSI surveillance, and not understanding the extent of home infusion CLABSI
morbidity and mortality.16,21 Our consensus candidate deﬁnition may
reduce variation among home care providers in what is used for a
home infusion CLABSI surveillance deﬁnition.
The numerator deﬁnition sparked much debate. In particular, difﬁculties with sufﬁcient patient monitoring to record speciﬁc signs
and symptoms were thought to make the NHSN deﬁnition7 difﬁcult
to implement (although wearable monitors may be options in the
future). Many respondents noted that the NHSN acute care CLABSI
deﬁnition would be unwieldy to implement in home infusion therapy.7 Similarly, although chills were part of the numerator criteria in
the deﬁnition chosen by the stakeholder panel, this is a subjective
symptom. It is very possible that subjective portions of the criteria
may be adjusted to be more measurable and replicable, pointing to
the need for validation of the deﬁnition. Meanwhile, for patients
under the age of 1, criteria chosen were the modiﬁcation of the acute
care CLABSI criteria for patients ≤1 years of age. The numerator criteria agreed upon by the expert panel should be carefully validated and
feasibility tested.
Denominator data was considered to be particularly labor intensive in CLABSI surveillance in the home. Staff is not in the homes
with patients on a daily basis, and patients may have their CVCs
removed or replaced in a radiology suite or acute care hospital without the home infusion agency or home nursing agency being immediately aware. Many home infusion electronic health records are not
designed to easily facilitate collection of catheter-day data. While

there was discussion of using a deﬁnition similar to a dialysis event
denominator (that is, the number of patients receiving services on
the ﬁrst 2 weekdays of a month22), there were concerns that this deﬁnition would be difﬁcult to compare with hospitals in the same
healthcare system. Also, our deﬁnition does not adjust for CVC-days
in acute care hospitals prior to discharge to home infusion. However,
obtaining this data and adjusting for it as a prehome infusion risk factor would be very difﬁcult without doing hand-calculations. In addition, when patients with CVCs at home are admitted to acute care
hospitals (for example, a patient on chemotherapy via a CVC placed
at another facility admitted for routine chemotherapy), acute care
hospitals do not adjust for preadmission CVC days, and our deﬁnition
is in keeping with this approach. We did not address the fact that
many patients may have CVCs indeﬁnitely; for example, those requiring HPN for short bowel syndrome or other conditions. Clearly this
impacts the denominator as well as numerator, and the impact of
this population of patients on CLABSI rates should be investigated.
Certain inclusion and exclusion criteria also prompted debate. For
example, patients with implanted ports may be intermittently accessing
and deaccessing these ports for years at a time. Whether these implanted
ports should be considered eligible for CLABSI for the entire length of
time that the implanted port is in place once accessed in the home was
unclear, so the expert panel elected to focus on those ports accessed
within 72 hour of the positive blood cultures. In addition, lack of access
to data around quantitative diarrhea volume and recent white blood cell
or neutrophil counts, and even blood culture results make mucosal barrier injury criteria difﬁcult to apply. Although mucosal barrier injury criteria were discussed by the members, these were not scored highly,
perhaps due to difﬁculties applying these criteria (particularly volume of
stool or recent blood test results) in the home infusion setting. In addition, although several participants suggested that criteria similar to
mucosal barrier injury criteria be developed for patients with short
bowel syndrome or signiﬁcantly immunocompromised who are on HPN,
these criteria were not ranked highly enough to be included. Although
there were conversations around excluding patients who receive products from one home infusion agency and education and evaluation from
a nonafﬁliated home nursing agency, or receive services from outpatient
infusion centers, the participants elected to include all patients in whom
there was contact with employed or contracted staff from the home infusion or home nursing agency. It was felt that this may mitigate training
variance between agencies. However, there was no consensus reached
on these inclusion or exclusion criteria (with the exception of those who
received home nursing from an unafﬁliated agency; the focus was on
CVCs that employed or contracted staff physically touched and patients
for whom these staff provided education).
The expert panel discussed difﬁculties in implementing a home
infusion CLABSI deﬁnition. Home infusion therapy is under-resourced
in both staff time available and in expertize in healthcare-associated
infection surveillance. In a recent study, less than 5% of respondents
reported that their home infusion therapy agency employed someone with a certiﬁcation in infection control.16 Therefore, a CLABSI definition must be relatively simple to implement. It is important to
know whether different home infusion therapy agencies may implement this deﬁnition in the same way.78 Further work is needed to
determine this deﬁnition’s feasibility and validity.
In acute care, CLABSI deﬁnitions have been used and modiﬁed
over the years.4,7,9,79 Our home infusion CLABSI deﬁnition may also
require modiﬁcations based on feedback and experience. Interestingly, the CLABSI candidate criteria included modiﬁcations of the
NHSN acute care CLABSI deﬁnition,7 the 2008 APIC-HICPAC home
infusion bloodstream infection deﬁnition,14 the NHSN dialysis event
deﬁnition,22 the NNIS acute care CLABSI deﬁnition,23,24 and that proposed in 2000 as a draft deﬁnition for home infusion CLABSI surveillance.24 Our deﬁnition may also need to be modiﬁed based on
experience.
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Having a clear deﬁnition for CLABSI in acute care hospitals has
allowed for comparisons between acute care hospitals as well as
target-setting to drive CLABSI prevention efforts.80 With a deﬁnition
of home infusion CLABSI, home infusion, home care, and home hospice agencies can begin the work of benchmarking data and then
identifying interventions which may reduce home infusion CLABSI.
This study had limitations. We sought representation from stakeholders involved in home infusion CLABSI surveillance, but several
experts were unable to participate. It is also possible we missed certain studies or approaches in our literature search. We tried to identify other sources by searching through references and asking
experts. Our identiﬁed deﬁnition has not yet been validated or tested
for feasibility and validation and feasibility testing is needed before
the deﬁnition is widely implemented. In addition, our ﬁnal criteria
did not contain exclusion criteria for stem cell transplant, bone marrow transplant, neutropenic, or certain patients receiving. Future
work may add these or other populations as exclusion criteria. For
the denominator criteria, 3 very similar deﬁnitions were each rated
highly and we chose the most inclusive criteria as the ﬁnal criterion.
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CONCLUSIONS
16.

We have developed a candidate home infusion CLABSI deﬁnition.
While work needs to be done to validate, test its feasibility, and
benchmark the deﬁnition, this serves as an expert-driven basis for
beginning work to measure, deﬁne, and reduce CLABSI rates in home
infusion therapy. This candidate surveillance deﬁnition developed by
expert consensus is a method by which we can perform surveillance
to understand the burden of home infusion CLABSI. We can use this
deﬁnition to perform internal and industry-wide preventative strategies to drive down CLABSI rates. As Medicare begins to expand payments for home infusion therapy, understanding the incidence of
CLABSI in the home infusion setting is essential.
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